Advances in ovarian cancer therapy.
Advances in ovarian cancer therapy.
复制标题
DOI：
10.1007/s00280-017-3501-8
复制
发表时间：
2018-01
影响因子：
3
通讯作者：
Lisowska KM
中科院分区：
文献类型：
--
作者：
Cortez AJ;Tudrej P;Kujawa KA;Lisowska KM
卵巢上皮癌通常在晚期被诊断。目前最先进的手术和化疗导致完全缓解的发生率很高;然而，复发率也很高。对于大多数患者，疾病最终成为一个连续的无瘤期和复发发作。目前正在开发的不同靶向治疗方法和生物药物有望将卵巢癌转变为可管理的慢性疾病。在这篇综述中，我们讨论了目前的标准治疗卵巢癌，主要最近研究的新变种的传统疗法，和新的治疗方法，最近批准和/或在临床试验。后者包括抗血管生成疗法、聚ADP-核糖聚合酶（PARP）抑制剂、生长因子信号传导抑制剂或叶酸受体抑制剂，以及几种免疫疗法。我们还讨论了一些新疗法的成本效益和更好地选择患者进行个性化治疗的问题。
Epithelial ovarian cancer is typically diagnosed at an advanced stage. Current state-of-the-art surgery and chemotherapy result in the high incidence of complete remissions; however, the recurrence rate is also high. For most patients, the disease eventually becomes a continuum of symptom-free periods and recurrence episodes. Different targeted treatment approaches and biological drugs, currently under development, bring the promise of turning ovarian cancer into a manageable chronic disease. In this review, we discuss the current standard in the therapy for ovarian cancer, major recent studies on the new variants of conventional therapies, and new therapeutic approaches, recently approved and/or in clinical trials. The latter include anti-angiogenic therapies, polyADP-ribose polymerase (PARP) inhibitors, inhibitors of growth factor signaling, or folate receptor inhibitors, as well as several immunotherapeutic approaches. We also discuss cost-effectiveness of some novel therapies and the issue of better selection of patients for personalized treatment.
登录
查看更多内容
影响因子：
4.7
作者：
Aghajanian C;Goff B;Nycum LR;Wang YV;Husain A;Blank SV
通讯作者：
Blank SV
影响因子：
4.7
作者：
Armstrong, Deborah K.;White, Allen J.;Coleman, Robert L.
通讯作者：
Coleman, Robert L.
影响因子：
4.7
作者：
Colombo, Nicoletta;Mangili, Giorgia;Chamberlain, Donald
通讯作者：
Chamberlain, Donald
影响因子：
4
作者：
Aravantinos G;Pectasides D
通讯作者：
Pectasides D
影响因子：
--
作者：
Borlak J;Länger F;Spanel R;Schöndorfer G;Dittrich C
通讯作者：
Dittrich C